Professional Documents
Culture Documents
pro-BNP Angiotensinogen
(liver secretion)
Angiotensin I
BNP
Neprilysin N
OH
Inactive
X HN
O
HO
O
OH
N
N
X AT1 receptor
NH
N
fragments O
Plasma NT-proBNP > 400 pg/ml at screening Dyspnea and/or edema from non-cardiac
(Visit 1) causes, such as lung disease, anemia, or
severe obesity
On diuretic therapy prior to Visit 1, controlled
systolic BP (<140 mm Hg, or BP <160 mm Hg if Presence of valvular heart disease,
on 3 meds) hypertrophic cardiomyopathy, infiltrative
cardiomyopathy, restrictive cardiomyopathy, or
eGFR ≥ 30 ml/min/1.73 m2 (MDRD) pericardial disease
Patients with a potassium ≤5.2 mmol/l at Visit 1 Coronary disease requiring revascularization
during the study
PARAMOUNT: Study Design
LCZ696 LCZ696
50 mg BID 100 mg BID LCZ696 200 mg BID
Placebo run-in
Discontinue ACEI or Valsartan Valsartan
40 mg BID 80 mg BID Valsartan 160 mg BID
ARB therapy one day
prior to randomization
Prior ACEi/ARB use discontinued
Week -2 0 1 2 4 8 12 18 24 30 36
Visit 1 2 3 4 5 6 7 8 9 10 11
Primary
NT pro-BNP reduction from baseline at 12 weeks
objective
Echocardiographic measures of diastolic function, left atrial size, LV size and function,
Secondary PASP
objectives HF symptoms, Clinical composite assessment and Quality of life (KCCQ)
Safety and tolerability
LCZ696 200 mg, n=149 (100%) patients Valsartan 160 mg, n=152 (100%) patients
Baseline Echocardiographic
Measures
Left Ventricular Ejection Fraction (%) 58 (7.3) 58 (8.1)
Left Ventricular Ejection Fraction ≥ 76% 82%
50%
Lateral Mitral Relaxation Velocity (E’) 7.8 (2.7) 7.3 (2.9)
(cm/s)
Mitral Inflow to Mitral Relaxation 12.4 (8.1) 13.0 (7.0)
Velocity Ratio (E/E’ )
Left Atrial Dimension (cm) 3.7 (0.45) 3.7 (0.54)
Left Atrial Volume (ml) 65.6 (22.7) 67.4 (28.4)
Left Ventricular mass (g) 145 (40.5) 150 (43.8)
Primary Endpoint: NT-proBNP at 12 Weeks
900
Valsartan
NTproBNP (pg/ml)
800
700
LCZ696
600
p = 0.063 LCZ696/Valsartan:
500
0.77 (0.64, 0.92)
400 P = 0.005
783 (670,914) 605 (512, 714)
300
200
0 5 10 12
Weeks Post Randomization
Similar Treatment Effect in All Predefined Subgroups
Interaction P-Value
Age ≥ 65 n = 207
Age < 65 n = 59 P = 0.57
Female n = 114
Male n = 152 P = 0.69
SBP > 140 n = 88
SBP ≤ 140 n = 178 P = 0.07
eGFR ≥ 60 n = 153
P = 0.18
eGFR < 60 n = 109
1000
900
Valsartan
800
NTproBNP (pg/ml)
700
600
p = 0.063 p = 0.005
500
p = 0.20
400
LCZ696
300
200
0 5 10 15 20 25 30 35 40
Weeks Post Randomization
Blood Pressure Reduction
12 weeks 36 weeks
SBP DBP SBP DBP
0
Change in Blood Pressure (mm Hg)
-1
-2
LCZ696
-3 VALSARTAN
-4
-5
-6
-7
-8
-9
P = 0.006 P = 0.001
-10 P = 0.001 P = 0.09
LCZ696
1
Valsartan
-1
-2 -0.10
-3
-4
-0.15
-5
P = 0.18 P = 0.003
P = 0.07 P = 0.03
-6
-0.20
2.0
E/E’
-0.8
-1.0
0.5
-1.2
-1.4
-1.6 0.0
12 weeks 36 weeks
-1.8
P = 0.71 P = 0.42
-2.0
Worsened
Unchanged
Improved
110
P = 0.11 P = 0.05
100
90
Percent of Patients
80
70
60
50
40
30
20
10
0
LCZ696 Valsartan LCZ696 Valsartan
Week 12 Week 36
Adverse Events and Laboratory Values
LCZ696 Valsartan p-value
(n=149) (n=152)
Any Serious Adverse 22 (15%) 30 (20%) 0.32
Event (SAE)
Deaths 1 (0.7%) 2 (1.3%) 0.99
All Cardiac 9 (6.0%) 12(7.9%) 0.69
Heart Failure 4 (2.7%) 6 (3.9%) 0.77
Any Adverse Event (AE) 96 (64%) 111 (73%) 0.14
Adverse events of
Interest
Symptomatic 28 (19%) 27 (18%) 0.88
Hypotension
Renal Dysfunction 3 (2.0%) 7 (4.6%) 0.34
Hyperkalemia 12 (8.1%) 9 (5.9%) 0.50
Abnormal Laboratory
Values
Potassium > 5.5 24 (16%) 16 (11%) 0.21
Potassium ≥ 6.0 5 (3.4%) 6 (4.2%) 0.97
≥ 50% decrease in eGFR 5 (3.4%) 4 (2.8%) 0.98
Conclusions